VTCN1 and urinary bladder cancer: Blocking both PD-L1 and B7H4 by monoclonal antibodies resulted in less advanced tumour stage, tumour growth inhibition, and enhanced necrosis within the tumour, highlighting the potential usability of B7H4 inhibitors in bladder cancers unresponsive to the PD-1/PD-L1 blockade [94].